Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18680187 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSES | May 2024 | May 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18403883 | FLAVIVIRUS VACCINE | January 2024 | September 2025 | Allow | 20 | 2 | 1 | No | No |
| 18566986 | SENSOR FOR DETECTING BIOMARKERS IN A FLUID SAMPLE AND METHODS OF USE | December 2023 | November 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18527150 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | December 2023 | January 2026 | Abandon | 26 | 4 | 0 | Yes | No |
| 18503260 | STABILIZED CORONAVIRUS SPIKE (S) PROTEIN IMMUNOGENS AND RELATED VACCINES | November 2023 | August 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18366310 | MUTATED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR CHEMICAL COUPLING OF LIGANDS, NANOPARTICLES OR DRUGS VIA THIOETHER BINDING AND PRODUCTION METHOD THEREOF | August 2023 | October 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18330194 | BROADLY REACTIVE IMMUNOGENS OF DENGUE VIRUS, COMPOSITIONS, AND METHODS OF USE THEREOF | June 2023 | March 2026 | Abandon | 33 | 2 | 1 | No | No |
| 18309475 | ANTI-RSV MONOCLONAL ANTIBODY FORMULATION | April 2023 | December 2025 | Abandon | 31 | 3 | 1 | No | No |
| 18181974 | Separation Method | March 2023 | June 2025 | Allow | 28 | 2 | 0 | No | No |
| 18064299 | IMMUNOGENIC COMPOSITIONS OF HEPATITIS C VIRUS AND USES THEREOF | December 2022 | February 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 18052402 | Virus-like particles containing RSV antigen protein and vaccines using the same | November 2022 | March 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17958148 | VACCINE FORMULATIONS WITH INCREASED STABILITY | September 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17937234 | Vectors for Producing Virus-Like Particles and Uses Thereof | September 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17802361 | CORONAVIRUS VACCINES COMPRISING A TLR9 AGONIST | August 2022 | February 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17881816 | RABBIT HAEMORRHAGIC DISEASE VIRUS (RHDV) VACCINES | August 2022 | August 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17797570 | MEASLES-VECTORED COVID-19 IMMUNOGENIC COMPOSITIONS AND VACCINES | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17879265 | Compositions for Determining Vaccine Potency | August 2022 | September 2025 | Allow | 37 | 5 | 1 | No | No |
| 17795261 | REGULATORY T CELL EPITOPES AND DETOLERIZED SARS-COV-2 ANTIGENS | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17792133 | TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS | July 2022 | January 2026 | Allow | 42 | 1 | 1 | Yes | No |
| 17790259 | ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME | June 2022 | December 2025 | Allow | 42 | 1 | 0 | No | No |
| 17786310 | POWASSAN VIRAL ANTIGENS AND RELATED COMPOSITIONS, AND USES THEREOF TO VACCINATE AND TREAT PATIENTS | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17784605 | MUMPS AND MEASLES VIRUS IMMUNOGENS AND THEIR USE | June 2022 | January 2026 | Allow | 44 | 1 | 1 | Yes | No |
| 17775094 | ZIKA/DENGUE VACCINE AND APPLICATION THEREOF | May 2022 | January 2026 | Allow | 45 | 2 | 1 | No | No |
| 17730043 | VACCINES FOR TREATING SARS INFECTIONS IN CANCER PATIENTS | April 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17753943 | COMBINATION OF A POXVIRUS ENCODING HPV POLYPEPTIDES WITH AN ANTI-PD-L1 ANTIBODY | March 2022 | December 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17642791 | CHIMERIC FILOVIRUS VACCINES | March 2022 | September 2025 | Allow | 42 | 1 | 0 | No | No |
| 17642795 | LASSAVIRUS VACCINES | March 2022 | May 2025 | Allow | 38 | 0 | 0 | No | No |
| 17632943 | CHIKUNGUNYA VACCINE FORMULATIONS | February 2022 | December 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17632946 | SINGLE SHOT CHIKUNGUNYA VIRUS VACCINE | February 2022 | December 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17629115 | POLYPEPTIDES FOR TREATMENT OF AML | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17616939 | HEPATITIS B VIRUS-SPECIFIC T CELL RESPONSES | December 2021 | February 2026 | Allow | 50 | 1 | 1 | Yes | No |
| 17595889 | M1 VIRUS MUTANT AND USE THEREOF | November 2021 | September 2025 | Allow | 46 | 2 | 1 | No | No |
| 17507604 | Surveillance of SARS-CoV-2 Through Mask Testing | October 2021 | March 2026 | Abandon | 53 | 1 | 1 | Yes | No |
| 17602951 | CD40 Specific DNA Aptamers as Vaccine Adjuvants | October 2021 | August 2025 | Allow | 46 | 1 | 1 | No | No |
| 17291984 | ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS | May 2021 | February 2026 | Allow | 57 | 1 | 1 | Yes | No |
| 17158431 | VITRO PREDICTION OF IN VIVO HALF-LIFE | January 2021 | July 2025 | Allow | 54 | 5 | 1 | Yes | No |
| 16739724 | ANTIBODY PURIFICATION AND PURITY MONITORING | January 2020 | December 2025 | Allow | 60 | 7 | 1 | No | No |
| 16172487 | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS | October 2018 | January 2019 | Allow | 3 | 1 | 0 | No | No |
| 16047524 | RSV-SPECIFIC BINDING MOLECULE | July 2018 | March 2020 | Allow | 20 | 1 | 1 | Yes | No |
| 15545337 | ANTI-VIRAL COMPOSITIONS CONTAINING PIKFYVE INHIBITORS AND USE THEREOF | July 2017 | April 2020 | Allow | 33 | 2 | 1 | Yes | No |
| 15605745 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES | May 2017 | June 2018 | Allow | 12 | 0 | 0 | No | No |
| 15523899 | METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT | May 2017 | April 2019 | Allow | 24 | 1 | 1 | Yes | No |
| 15404662 | MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINS | January 2017 | April 2019 | Allow | 27 | 2 | 1 | Yes | No |
| 15315667 | METHOD FOR RAPID GENERATION OF AN INFECTIOUS RNA VIRUS | December 2016 | April 2019 | Allow | 29 | 1 | 1 | Yes | No |
| 15315687 | METHOD FOR RAPID GENERATION OF AN ATTENUATED RNA VIRUS | December 2016 | December 2019 | Allow | 36 | 2 | 2 | Yes | No |
| 15204077 | DNA VACCINE AGAINST VIRUS OF YELLOW FEVER | July 2016 | April 2018 | Allow | 21 | 1 | 0 | Yes | No |
| 15032338 | LIVE ATTENUATED INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILTV) VACCINES AND PREPARATION THEREOF | April 2016 | September 2018 | Allow | 29 | 2 | 1 | No | No |
| 15132436 | Pestivirus Species | April 2016 | April 2018 | Allow | 24 | 1 | 1 | Yes | No |
| 14935281 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF VACCINES AGAINST DENGUE VIRUS | November 2015 | February 2018 | Allow | 28 | 2 | 0 | Yes | No |
| 14652066 | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES FOR TRIVALENT DENGUE VIRUS FORMULATIONS | June 2015 | September 2017 | Allow | 27 | 2 | 1 | Yes | No |
| 14439967 | EFFECT OF HBV ON CLINICAL OUTCOME OF HEPATOCELLULAR CARCINOMA CANCER PATIENTS | April 2015 | January 2018 | Allow | 33 | 4 | 0 | No | No |
| 14429559 | VIRUSES ASSOCIATED WITH IMMUNODEFICIENCY AND ENTEROPATHY AND METHODS USING SAME | March 2015 | February 2017 | Allow | 23 | 1 | 1 | Yes | No |
| 14407012 | COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS | December 2014 | March 2017 | Allow | 27 | 2 | 1 | Yes | No |
| 14400642 | CROSS-REACTIVE ANTIBODIES AGAINST DENGUE VIRUS AND USES THEREOF | November 2014 | September 2016 | Allow | 22 | 1 | 1 | Yes | No |
| 14182731 | NOVEL NEUTRALIZING IMMUNOGEN (NIMIV) OF RHINOVIRUS AND ITS USES FOR VACCINE APPLICATIONS | February 2014 | March 2016 | Allow | 25 | 1 | 1 | Yes | No |
| 14165126 | T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTION | January 2014 | April 2016 | Allow | 26 | 1 | 1 | Yes | No |
| 14090221 | ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS | November 2013 | April 2016 | Allow | 29 | 2 | 0 | No | No |
| 14039148 | RSV SPECIFIC BINDING MOLECULE | September 2013 | October 2015 | Allow | 25 | 1 | 1 | Yes | No |
| 14036412 | PESTIVIRUS SPECIES | September 2013 | January 2016 | Allow | 28 | 2 | 1 | No | No |
| 13984702 | COMBINATION OF BIOMARKERS FOR THE DETECTION AND EVALUATION OF HEPATITIS FIBROSIS | August 2013 | December 2016 | Allow | 40 | 3 | 1 | No | No |
| 13942064 | RECOMBINANT BICISTRONIC FLAVIVIRUS VECTORS | July 2013 | August 2015 | Allow | 25 | 1 | 1 | Yes | No |
| 13825049 | RECOMBINANT FLAVIVIRAL CONSTRUCTS AND USES THEREOF | June 2013 | May 2015 | Allow | 26 | 2 | 0 | Yes | No |
| 13740100 | DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES | January 2013 | May 2015 | Allow | 28 | 3 | 0 | Yes | No |
| 13633436 | Replication-Defective Flavivirus Vaccines and Vaccine Vectors | October 2012 | August 2015 | Allow | 34 | 2 | 1 | Yes | No |
| 13504464 | DNA VACCINE AGAINST VIRUS OF YELLOW FEVER | August 2012 | March 2016 | Allow | 46 | 2 | 1 | Yes | Yes |
| 13492884 | COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS | June 2012 | October 2014 | Allow | 28 | 2 | 1 | Yes | No |
| 13406153 | RECOMBINANT FLAVIVIRUS VACCINES | February 2012 | June 2014 | Allow | 28 | 2 | 1 | Yes | No |
| 13321460 | Compositions And Methods For The Therapy And Diagnosis Of Influenza | February 2012 | January 2014 | Allow | 26 | 2 | 1 | Yes | No |
| 13357189 | NOVEL ANTIVIRAL PEPTIDES AGAINST INFLUENZA VIRUS | January 2012 | August 2015 | Allow | 43 | 2 | 1 | No | No |
| 13309498 | MULTI PLASMIDS SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS | December 2011 | November 2012 | Allow | 12 | 1 | 0 | No | No |
| 13274285 | DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES | October 2011 | January 2014 | Allow | 27 | 5 | 0 | Yes | No |
| 13230209 | DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, NUCLEOTIDE SEQUENCE AND ANTIBODY COMPOSITION | September 2011 | April 2014 | Allow | 31 | 2 | 1 | No | No |
| 13130559 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 | September 2011 | August 2014 | Allow | 39 | 2 | 1 | Yes | No |
| 13130554 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 | September 2011 | August 2014 | Allow | 39 | 2 | 1 | Yes | No |
| 13199348 | Host cell specific binding molecules capable of neutralizing viruses and uses thereof | August 2011 | August 2014 | Allow | 35 | 1 | 0 | No | No |
| 13190547 | Assay for the diagnosis of flaviviral infection using antibodies with high affinity for NS1 protein of flavivirus in hexameric form | July 2011 | December 2013 | Allow | 28 | 4 | 1 | Yes | No |
| 13102685 | DENGUE CHIMERIC VIRUSES | May 2011 | March 2012 | Allow | 11 | 0 | 1 | Yes | No |
| 12995024 | EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOF | January 2011 | June 2015 | Allow | 54 | 6 | 1 | Yes | No |
| 12922513 | REPLICATION-DEFECTIVE FLAVIVIRUS VACCINES AND VACCINE VECTORS | December 2010 | April 2014 | Allow | 43 | 2 | 1 | No | No |
| 12956460 | FLAVIVIRUS FUSION INHIBITORS | November 2010 | December 2011 | Allow | 12 | 1 | 1 | Yes | No |
| 12808565 | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 6A | November 2010 | June 2013 | Allow | 36 | 1 | 1 | No | No |
| 12809345 | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 1A AND 1B | November 2010 | June 2013 | Allow | 36 | 1 | 1 | Yes | No |
| 12600349 | EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 5A | October 2010 | June 2013 | Allow | 43 | 1 | 1 | Yes | No |
| 12809348 | PRE-OR POST-EXPOSURE TREATMENT FOR FILOVIRUS OR ARENAVIRUS INFECTION | September 2010 | March 2014 | Allow | 45 | 4 | 1 | Yes | No |
| 12301961 | MYXOMA VIRUS MUTANTS FOR CANCER TREATMENT | September 2010 | April 2013 | Allow | 53 | 2 | 1 | Yes | No |
| 12869526 | Preparation of Vaccines Using Photosensitizer and Light | August 2010 | February 2014 | Allow | 41 | 4 | 1 | No | No |
| 12309670 | METHODOLOGY FOR DETECTION, ENUMERATION, PROPAGATION AND MANIPULATION OF BACTERIOPHAGES | August 2010 | November 2012 | Allow | 45 | 1 | 0 | Yes | No |
| 12842854 | METHODS AND COMPOSITIONS FOR EXPRESSING NEGATIVE-SENSE VIRAL RNA IN CANINE CELLS | July 2010 | June 2012 | Allow | 22 | 1 | 1 | Yes | No |
| 12836856 | Compositions and Methods Using Herpes Simplex Virus | July 2010 | February 2014 | Allow | 43 | 2 | 1 | Yes | No |
| 12795506 | IMMUNOPROTECTIVE INFLUENZA ANTIGEN AND ITS USE IN VACCINATION | June 2010 | May 2011 | Allow | 11 | 2 | 0 | Yes | No |
| 12793092 | Surrogate Markers for Viral Infections and Other Inflammatory Responses | June 2010 | July 2014 | Allow | 49 | 3 | 1 | Yes | Yes |
| 12594756 | MONOCLONAL ANTIBODIES AGAINST DENGUE AND OTHER VIRUSES WITH DELETION IN FC REGION | June 2010 | August 2012 | Allow | 34 | 1 | 0 | Yes | No |
| 12790511 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF VACCINES AGAINST DENGUE VIRUS | May 2010 | August 2015 | Allow | 60 | 5 | 1 | Yes | No |
| 12790618 | IDENTIFICATION OF ASTROVIRUS VA1 ASSOCIATED WITH GASTROENTERITIS IN HUMANS | May 2010 | December 2012 | Allow | 31 | 2 | 1 | Yes | No |
| 12525168 | FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS | May 2010 | July 2013 | Allow | 48 | 2 | 1 | Yes | No |
| 12442988 | NOVEL NEUTRALIZING IMMUNOGEN (NIMIV) OF RHINOVIRUS AND ITS USE FOR VACCINE APPLICATIONS | May 2010 | September 2013 | Allow | 54 | 2 | 2 | Yes | No |
| 12770905 | EXPRESSION OF HIV POLYPEPTIDES AND PRODUCTION OF VIRUS-LIKE PARTICLES | April 2010 | September 2011 | Allow | 16 | 1 | 1 | Yes | No |
| 12664778 | METHOD FOR THE DIAGNOSIS OR THE SCREENING OF AN ARBOVIRUS INFECTION, REAGENTS USEFUL IN SAID METHOD AND THEIR APPLICATIONS | April 2010 | September 2012 | Allow | 33 | 2 | 1 | Yes | No |
| 12594774 | METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY INHIBITING THE DelSGYLATION ACTIVITY OF OTU DOMAIN-CONTAINING VIRAL PROTEINS | March 2010 | November 2013 | Allow | 50 | 2 | 2 | No | No |
| 12733920 | FORMULATIONS FOR PRESERVATION OF ROTAVIRUS | March 2010 | April 2012 | Allow | 25 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, STACY BROWN.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 37.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHEN, STACY BROWN works in Art Unit 1672 and has examined 254 patent applications in our dataset. With an allowance rate of 97.6%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner CHEN, STACY BROWN's allowance rate of 97.6% places them in the 89% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHEN, STACY BROWN receive 2.43 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHEN, STACY BROWN is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -2.8% benefit to allowance rate for applications examined by CHEN, STACY BROWN. This interview benefit is in the 7% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 28.2% of applications are subsequently allowed. This success rate is in the 51% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 60.3% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 90.0% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 72.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 68.9% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 31.1% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.3% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.